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Abstract
The dysregulation of receptor protein tyrosine kinase (RPTK) function can result in changes in cell proliferation, cell growth
and metastasis leading to malignant transformation. Among RPTKs, the TAM receptor family composed of three members
Tyro3, Axl, and Mer has been recognized to have a prominent role in cell transformation. In this study we analyzed the
consequences of Tyro3 overexpression on cell proliferation, activation of signaling pathways and its functional interactions
with Axl. Overexpression of Tyro3 in the Rat2 cell line that expresses Axl, but not Mer or Tyro3, resulted in a 5 fold increase in
cell proliferation. This increase was partially blocked by inhibitors of the mitogen-activated protein kinase (MAPK) signaling
pathway but not by inhibitors of the phosphatidylinositol 3-kinase (PI(3)K) signaling pathway. Consistent with these
findings, an increase in ERK1/2 phosphorylation was detected with Tyro3 but not with Axl overexpression. In contrast,
activation of Axl stimulated the PI(3)K pathway, which was mitigated by co-expression of Tyro3. The overexpression of Tyro3
enhanced Gas6-mediated Axl phosphorylation, which was not detected upon overexpression of a ‘‘kinase dead’’ form of
Tyro3 (kdTyro3). In addition, the overexpression of Axl induced kdTyro3 phosphorylation. Co-immunoprecipitation
experiments confirmed that the Axl and Tyro3 receptors are closely associated. These findings show that overexpression of
Tyro3 in the presence of Axl promotes cell proliferation, and that co-expression of Axl and Tyro3 can affect the outcome of
Gas6-initiated signaling. Furthermore, they demonstrate a functional interaction between the members of the TAM receptor
family which can shed light on the molecular mechanisms underlying the functional consequences of TAM receptor
activation in cell transformation, neural function, immune function, and reproductive function among others.
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Introduction
Cell proliferation is one of the basic cellular processes driving
normal development, tissue repair and renewal. Receptor protein
tyrosine kinases (RPTKs) are key regulators of proliferation and
alteration of their function and that of their downstream targets
can lead to malignant transformation [1,2,3,4]. In this study we
addressed the proliferative and signaling properties of the receptor
Tyro3, and its ability to interact with its related receptor Axl. The
TAM RPTK receptor family is composed of 3 structurally related
members, Tyro3, Axl and Mer [5]. Two related proteins, protein
S and Gas6, serve as ligands for the TAMs [6,7]. Gas6 can bind
and activate all three receptors, with binding affinities in the nM
range [8,9,10,11]. Functional studies have shown that the TAMs
play an important role in the immune response by regulating the
phagocytosis of apoptotic cells [12], the direct suppression of the
inflammatory response [13], and the differentiation of natural
killer cells [14]. In addition to their ability to regulate the immune
response [15], these receptors have also been implicated in blood
coagulation [16,17], reproduction [18,19,20], diabetic nephropa-
thy [21], and CNS function [22,23,24].
The 3 TAMs are upregulated in tumors of diverse origin and
are frequently overexpressed in transformed cells [16,25,26]. The
transforming potential of Tyro3 has been demonstrated by its
ability to induce anchorage-independent growth on soft agar in
fibroblastic cell lines and malignant melanoma cells [26,27,28,29].
In addition, when injected into nude mice, Rat1b fibroblasts
overexpressing Tyro3 stimulate tumor formation [28] and
knockdown of Tyro3 in malignant melanoma cells decreases their
proliferation [26]. Gas6 has been shown to induce cell pro-
liferation via either Axl or Mer. However, it should be noted that
in most of these studies the specific complement of TAMs
expressed was not determined. For example, in NIH 3T3 cells,
Gas6 signaling through Axl induced cell-cycle reentry via the
activation of phosphatidylinositol 3-kinase PI(3)K and Src but
a potential role for Tyro3 was not investigated [30,31]. Gas6 has
also been shown to elicit a proliferative response in rat vascular
smooth muscle endothelia (VSMC) [32,33], cardiac fibroblasts
[34], mesangial cells [35], prostate cells [36] and Schwann cells
[37]. In vivo studies also support a mitogenic role for Gas6 in
tumors of diverse origin [38]. As Gas6 can activate all 3 TAMs, it
is important to identify the complement of TAMs responsible for
Gas6 mediated proliferation.
Cross-talk among cell surface receptors of several classes has
been widely documented. In addition to forming homo- and
heterodimers [4], RPTKs can be trans-activated by other receptor
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Studies addressing the interaction of the TAMs with each other
and other receptors have been limited. One study has provided
evidence for the co-immunoprecipitation of Axl and Tyro3 in
a neuronal cell line suggesting a close association between these
receptors [20]. In addition Axl has been shown to co-precipitate
with IFNAR1 [13]. Other studies using TAM knockout mice have
supported the concept that the receptors functionally interact
[40,41,42], and at least two studies using these mice have reported
that the presence of one TAM affects the phosphorylation of
another TAM [41,42]. In order to understand the mechanisms
driving the transforming potential of Tyro3, the least characterized
member of the TAMs, we studied its proliferative and signaling
properties in the presence of Axl. When Tyro3 is overexpressed in
Rat2 cells, a cell line that expresses Axl but not Tyro3 or Mer,
Gas6 activation led to an increase in cell proliferation. This effect
was mediated in part by activation of the mitogen-activated
protein kinase (MAPK) signaling pathway but not influenced by
the PI(3)K pathway. The co-expression of Tyro3 and Axl
influenced the response to Gas6 as the introduction of Tyro3 led
to a reduction in PI(3)K pathway signaling and an increase in
MAPK pathway signaling. The overexpression of Tyro3 increased
the tyrosine phosphorylation of Axl, while a kinase inactive form of
Tyro3 lacked this ability. The cross-phosphorylation between
Tyro3 and Axl along with their ability to co-precipitate suggest
that they are closely associated. These findings also indicated that
the co-expression of combinations of TAM receptors, in this case
Tyro3 and Axl, can influence the outcome of Gas6-initiated
signaling and lead to changes in cell function.
Results
Characterization of TAM Expression in Rat2 and Rat2/
T3V5 Cells
We first characterized antibodies against individual TAM
receptors to determine their specificity. Tyro3 and Mer immuno-
precipitates were prepared from total brain extracts obtained from
wild-type (wt), tyro3
2/2 and mer
2/2 knockout mice, while
immunoprecipitates for Axl were prepared from wt and axl
2/2
knockout mouse spleens. Western blotting was performed with
immunoprecipitates of Tyro3, Axl and Mer, using antibodies
directed against each of these receptors. As shown in Fig. 1A (top
panel), anti-Tyro3 antibodies only recognize Tyro3 in wt (
+/+)
extracts (lane 1) but not in those derived from the tyro3
2/2 mice
(lane 2). Furthermore this antibody did not recognize proteins
immunoprecipitated with the anti-Axl (lanes 3–4) and anti-Mer
antibodies (lanes 5–6). Similarly, anti-Axl and anti-Mer antibodies
only recognized bands corresponding to their cognate receptors
(middle and bottom panels respectively). These results indicated
that the antibodies utilized for immunoprecipitation and Western
blotting are specific for each receptor of the TAM family.
As Gas6 is able to activate each of the 3 TAMs, we
characterized the expression of Tyro3, Axl and Mer receptors in
Rat2 cells and in a Rat2 cell line stably transfected with Tyro3
(Rat2/T3V5 cells). As shown in Fig. 1B, lane 1 untransfected Rat2
cells express Axl, but not Tyro3 or Mer, while the Rat2/T3V5
cells express both Tyro3 and Axl (lane 2). In the Rat2/T3V5 cells
Tyro3 appears as a doublet (Fig. 1B, lane 2 top panel and Fig. 1C
lane 1), although in brain Tyro3 appears mostly as a single band
(Fig. 1A lane 1, Fig. 1B, lane 3 and Fig. 1C lane 3) [22,27,43]. In
Rat2 cells both Tyro3 bands corresponded to N-linked glycosy-
lated forms, as did the Tyro3 band present in brain. Treatment
with N-Glycosidase F (PNGase F) resulted in molecular weight
changes giving rise to a single Tyro3 immunoreactive band of
approximately 95 kDa that was detected both in the Rat2 cells and
in brain (Fig. 1C lanes 2 and 4).
Gas6 Promotes the Proliferation of Rat2 Cells Transfected
with Tyro3
We tested whether the introduction of Tyro3 would promote
Gas6-mediated proliferation in Rat2 cells. Concentrations of Gas6
ranging from 0 to 500 ng/ml were evaluated, with a maximal
effect achieved between 100 and 250 ng/ml (not shown). These
concentrations are within those previously reported to induce
Gas6-mediated proliferation [36]. As shown in Fig. 2A, treatment
with 250 ng/ml of Gas6 induced a significant increase in cell
proliferation of the Rat2/T3V5 cells compared to the Rat2 cells at
all times points tested (24, 48 and 72 hrs). At 72 hrs, the increase
in optical density was 5 times greater than that observed for the
Rat2 cells.
In order to identify signaling candidates responsible for the
proliferative effects of Gas6, we tested pharmacological inhibitors
of molecules previously known to mediate Gas6 function. These
included an inhibitor of the MEK kinase (U0126), a component of
the MAPK signaling pathway, and two inhibitors of PI(3)K
(wortmannin and LY294002). The PI(3)K and MEK inhibitors
were first used to monitor the phosphorylation of AKT and
ERK1/2, downstream targets of PI(3)K and MEK respectively. As
shown in Fig. 2B, the inhibitors effectively blocked the Gas6-
mediated activation of these two signaling pathways, as demon-
strated by a reduction or elimination of AKT phosphorylation by
wortmannin and LY294002 and a concentration-dependent
reduction of ERK1/2 phosphorylation by U0126. When these
inhibitors were tested in the cell proliferation assay (Fig. 2C),
Gas6-induced cell proliferation as well as baseline proliferation in
the absence of Gas6 were not significantly affected by wortmannin
or LY294002. In contrast, treatment with the MEK inhibitor
U0126 led to a 30% reduction in baseline proliferation of the
Rat2/V5T3 cells in the absence of Gas6. In the presence of Gas6
the proliferation of MEK inhibitor treated cells increased
compared to control, but only to half the extent of that observed
in Gas6 stimulated cells. Gas6 could only partially overcome the
inhibition of cell proliferation of Rat/T3V5 cells. These results
suggested that the proliferative effect of Gas6 in Tyro3/Axl
expressing Rat2/T3V5 cells was mediated in part through
activation of the MAPK signaling pathway but not through
activation of PI(3)K.
Tyro3 Enhances ERK1/2 Signaling but Reduces Activation
of PI(3)K Signaling
In order to further identify the signaling requirements for
Tyro3-enhanced cell proliferation, we compared the activation of
the PI(3)K and MAPK signaling pathways in Rat2/T3V5 cells
expressing both Axl and Tyro3 (Fig. 3A, lanes 1–3) with the
untransfected Rat2 cells that only express Axl (Fig. 3A, lanes 4–6).
As shown in Fig. 3A (lanes 4–6), Gas6 activation in Rat2 cells,
which only express Axl, increased the phosphorylation of the
downstream targets of PI(3)K, pAKT, pp70S6K and pmTOR in
a concentration-dependent manner. Overexpression of Axl by
transient transfection (Fig. 3B, lanes 1–3) also led to an increase in
Gas6-mediated AKT phosphorylation. The increase in AKT/
p70S6K/mTOR phosphorylation caused by Gas6 in the Rat2/
T3V5 cells (Fig. 3A, lanes 1–3) was less than that observed in
untransfected cells (Fig. 3A, lanes 4–6). The difference in
phosphorylation of downstream PI(3)K targets in cells that only
express Axl compared to cells expressing Axl/Tyro3 is not due to
differences in overall levels of these molecules (Fig. 3C and 3D). In
Tyro3 and Axl, Signaling and Cross-Phosphorylation
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36800contrast, the phosphorylation of ERK1/2 was significantly
enhanced by Gas6 activation in the Tyro3 transfected cells
(Fig. 3A lanes 1–3), but not in the Axl overexpressing Rat2 cells
lacking Tyro3 (Fig. 3B lanes 1–3). Interestingly, higher levels of
pERK1/2 were detected in the untranfected cells, than in the Axl
overexpressing cells, while the total levels of ERK1/2 were
unchanged (Fig. 3D). These findings suggested that Tyro3 triggers
ERK1/2 activation and attenuates the activation of the PI(3)K
signaling pathway in Rat2/T3V5 cells. In addition, they
demonstrated that in Rat2 cells Axl does not significantly activate
ERK1/2, but does activate AKT, p70S6K and mTOR. The
differences in phosphorylation in ERK1/2, AKT, p70S6K and
mTOR observed in the presence of Axl and Tyro3 were not due
to changes in their total levels as these remained were unaltered by
overexpression of these receptors (see Fig. 3C and D).
Tyro3 Increases Gas6-induced Axl Tyrosine
Phosphorylation
We compared the ability of Gas6 to induce phosphorylation of
Tyro3 (Fig. 4A) and Axl (Fig. 4B) in cells expressing Axl (Rat2)
(lanes 1–3 both panels) and cells expressing both receptors (Rat2/
T3V5) (lanes 4–6 both panels). Gas6 induced only a modest
increase in phosphorylation of Axl in the untransfected cells (see
Fig. 4B lanes 1–3 and Fig. 4D lanes 1 and 2), when compared to
the higher Axl phosphorylation levels detected in the presence of
Tyro3 (Fig. 4B lanes 4–6 and Fig. 4D lanes 3–6). To control for
the possibility that higher levels of Axl phosphorylation were due
to higher levels of its expression, we compared Axl levels across 3
different stably transfected Tyro3 clonal (cl) cell lines exhibiting
different levels of Tyro3 expression (Fig. 4C, cl25 lane 2, cl11 lane
3, and cl30 lane 4 ). As shown in Fig. 4C no difference in total Axl
levels were detected across the cell lines. Therefore changes in Axl
phosphorylation in the presence of Tyro3 cannot be accounted for
by changes in Axl expression as also indicated by the data in
Fig. 3A. This suggests that increased levels of Axl phosphorylation
are caused by differences in the levels of Tyro3 expression. To
further test this possibility we used two of the clonal cell lines
expressing different levels of Tyro3 described in Fig. 4C and tested
whether increasing levels of Tyro3 would result in increased levels
of Axl phosphorylation upon Gas6 stimulation. As shown in
Fig. 4D, a small but detectable increase in Axl phosphorylation
was observed in the absence of Tyro3 (Fig. 4D lanes 1 and 2), but
Figure 1. Characterization of anti-TAM specific antibodies and TAM expression in Rat2 cells. To determine whether the antibodies used
to immunoprecipitate (IP) and detect Tyro3, Axl, and Mer ‘‘TAMS’’ by Western blotting were specific for each receptor, we used tissues derived
from knockout mice for each of the TAMS. Whole brain and spleen detergent extracts were prepared from wild-type (wt) (
+/+) C57BL/6 mice and
from tyro3
2/2, axl
2/2, and mer
2/2 knockout mice. As shown in panel A, After normalization for protein concentration, Tyro3 and Mer were IPed
from brain detergent extracts (lanes 1–2 and 5–6 respectively) and Axl was IPed from spleen extracts (lanes 3–4). Tyro3 was IPed using a-FN2, Axl
using #AF154 and Mer #AF591. SDS-PAGE was performed using 8% gels followed by Western blot analysis. The membranes were probed with a-
Tyro3 (5424 serum 1:3,000, top panel), affinity purified rabbit a-Axl (serum 1:3,500, center panel), and rabbit a-Mer (1:5,000 bottom panel).
These antibodies were used to characterize Tyro3, Axl, and Mer expression in Rat2 and Rat2/T3V5 cells as shown in panel B. Detergent cell
extracts were prepared from untransfected Rat2 cells (Rat, lane 1), stably Tyro3 transfected Rat2/T3V5 cells (Rat/T3 lane 2), brain tissue extract
(lane 3, top and bottom panels) or spleen tissue extract (lane3, center panel). After normalization of tissue extracts for protein
concentration, Tyro3, Axl and Mer were immunoprecipitated (IPed) (see Fig. 1A for antibodies). SDS-PAGE was performed using 8% gels followed
by Western blot analysis. The membranes were probed against Tyro3 (top panel), Axl (center panel), and Mer (bottom panel), as described in
Fig. 1A. The observed differences in Tyro3 molecular weight depending on the source are due in part by N-linked glycosylation as shown in panel
C. Detergent extracts were prepared from Rat2/T3V5 cells (Rat/T3, lanes 1 and 2), and adult rat brain tissue (brain, lanes 3 and 4). Cell and
tissue extracts were incubated overnight without (2) or with (+) PNGase F. SDS-PAGE was performed using 8% gels followed by Western blot
analysis using a-Tyro3 antibodies.
doi:10.1371/journal.pone.0036800.g001
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was present (lanes 3–6). Furthermore they were proportional to the
amount of Tyro3 present in the cells as observed when comparing
the levels of Axl phosphorylation in the lower Tyro3 expressing
clone (cl25 lanes 3 and 4) to the high Tyro3 expressing clone (cl30,
lanes 5 and 6).
Axl can Induce Phosphorylation of a Kinase Dead form of
Tyro3, and both Receptors Co-immunoprecipitate
In order to determine if the kinase activity of Tyro3 is required to
induce Axl phosphorylation, we generated a kinase inactive or
‘‘kinasedead’’construct(kdTyro3)bymutatingK535toM(K535M).
This results in a receptor that is unable to undergo autopho-
sphorylation [44], but that can still be trans-phosphorylated. As
showninFig.5Alane2,wefailedtodetecttyrosinephosphorylationof
thekdTyro3mutantwhenactivatedbyGas6incontrasttothesharp
increases in phosphotyrosine levels observed in the wild-type (wt)
Tyro3construct(comparekdT3,Fig.5lane2withwtT3,lane3).We
then compared Axl phosphorylation levels (Fig. 5B) in Rat2 cells
transientlytransfectedwitheitherkdTyro3(lane2)orwtTyro3(lane
3). As shown in Fig. 5B, Axl phosphorylation levels in untransfected
cells (that do not express Tyro3) (lane 1), are comparable to those
observed in cells transfected with the kdTyro3 construct (lane 2). In
contrast, in cells expressing wtTyro3 (lane 3) the levels of phosphor-
Figure 2. Gas6 induced cell proliferation of Rat2 and Rat2/T3V5 cells. Serum starved Rat2 and Rat2/T3V5 cells were stimulated with 250 ng/
ml of Gas6 for 0–72 hrs (panel A). Proliferative activity is expressed as % increase over the optical density (OD) obtained at 0 hrs which was
considered 0%. *=a significant increase in OD was observed in the Rat2/T3V5 cells when compared to Rat2 cells at 24, 48 and 72 hrs. p,0.01, two-
sample t-test. Each experiment consisted of 4 wells for each Rat2 and Rat2/T3V5. All comparisons for n=3 experiments. To determine the
effectiveness of the signaling pathway inhibitors (panel B), Rat/T3V5 cells were incubated 45 min prior to activation with vehicle (DMSO), 1.5 mM
LY294002, or 5.5 mM wortmannin (top panel) or with 1 mMo r1 0mM U0126 (bottom panel). The cells were activated with DMEM (-) or 350 ng/ml
of Gas6 (+) for 20 min. Detergent cell extracts normalized for protein concentration were separated by SDS-PAGE using 4–20% gels. Western blotting
was performed with a-pAKT (top panel), and a-pERK1/2 (bottom panel). The membranes were stripped and the blots were reprobed with a-
GAPDH shown beneath each panel as protein loading control. These blots are representative of 3 experiments. To determine the effects of the
signaling-pathway inhibitors on Gas6 mediated cell proliferation (panel C), serum starved cells were stimulated with DMEM only (control) or 250 ng/
ml of Gas6 for 72 hrs (Gas6) in the absence or presence of the indicated inhibitors. Proliferative activity is expressed as % increase of the optical
density (OD). The OD obtained in the absence of addition of Gas6 (control) or inhibitors was considered 100%. Asterisks * denote = a significant
increase in proliferation in the Gas6 treated cells relative to the untreated controls (*: p,0.05; **: p,0.01) two-sample t-test. The differences between
Gas6 treated cells and their respective controls for vehicle only, LY294002 and wortmannin (left panel) were found to be the same at p.0.05. The
differences between Gas6 treated cells and their controls for the two conditions, vehicle only, and U0126 (right panels) were different at p,0.01.
Comparisons are based on n=3 for the PI(3)K inhibitor panel (left) and n=4 for the MAPK inhibitor panel (right).
doi:10.1371/journal.pone.0036800.g002
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untransfectedcells(Fig.5,comparelane3withlane2inpanelsAand
B). These results indicated that the increase in Axl phosphorylation
observed uponTyro3 overexpression is dueto Tyro3activation.
Kinase inactive RPTKs can be trans-phosphorylated by their
catalytically active dimerization partners [45] or cross-phosphor-
ylated by other kinases [39]. In the experiment shown in Fig. 5A
lane 2, the phosphotyrosine levels of the kdTyro3 were not
detectable despite the presence of Axl (panel B). This low or lack of
phosphorylation may be attributed to the low endogenous levels of
Axl, which may be insufficient to noticeably increase the levels of
kdTyro3 phosphorylation. Indeed, even Axl itself is only weakly
activated in these cells in response to Gas6 (see Fig. 4B lanes 1–3,
Fig. 4D lanes 1–2 and Fig. 5B, lane 2). To determine if Axl is
capable of trans-phosphorylating kdTyro3, we boosted the levels
of Axl by co-transfecting Rat2 cells with Axl/kdTyro3 or Axl/
wtTyro3. As shown in Fig. 5C, the increased expression of Axl
(lanes 4–6) resulted in a notable elevation of kdTyro3 phosphor-
Figure 3. Tyro3 modulates MAPK and PI(3)K signaling pathways. As shown in panel A, Rat/T3V5 (Rat/T3, lanes 1–3) and Rat2 cells (Rat,
lanes 4–6) were treated with 0, 50, and 350 ng/ml of Gas6 for 20 min. Detergent cell extracts normalized for protein concentration were separated
by SDS-PAGE using 4–20% gels. Western blotting was performed with antibodies directed against a-Tyro3, a-Axl, a-pAKT, app70S6K, a-pmTOR, and
a-pERK1/2. The membranes were stripped or cut and reprobed with a-ERK1/2 or a-GAPDH and shown beneath each panel as protein loading control.
These blots are representative of 5 experiments. As shown in panel B, transiently transfected Rat2/Axl cells (Rat/Axl, lanes 1–3) and Rat2 cells (Rat,
lanes 4–6) were treated and processed as above. Western blotting was performed with a-Axl, a-pAKT, and a-pERK1/2. The membranes were cut and
reprobed with a-GAPDH shown beneath each panel as protein loading control. These blots are representative of 4 experiments. The total levels of
MAPK and PI(3)K signaling pathway molecules was compared in Rat2 cells overexpressing Tyro3 (panel C) and Axl (panel D). For Tyro3
overexpressing cells (panel C), Rat/T3V5 cells (Rat/T3, lanes 1–3), and Rat2 untransfected cells (Rat, lanes 4–6), were treated with 0, 50 and
350 ng/ml of Gas6 for 20 min. Detergent cell extracts normalized for protein concentration were separated by SDS-PAGE using 4–20% gels. Western
blotting was performed with antibodies directed against a-AKT, ap70S6K, a-mTOR. The membranes were cut and reprobed with a-GAPDH shown
beneath each panel as protein loading control. For total levels of Tyro3, Axl, and ERK1/2 in Rat2 and Rat2/T3V5 cells, see Fig. 3 A and B. These blots
are representative of 4 experiments. For Axl overexpressing cells (panel D), transiently transfected Rat2/Axl cells (Rat/Axl, lanes 1–3) and Rat2
untransfected cells (Rat, lanes 4–6) were treated and processed as above. Western blotting was performed with a-Axl, a-AKT, and a-ERK1/2. The
membranes were cut and reprobed with a-GAPDH shown beneath each panel as protein loading control. These blots are representative of 4
experiments.
doi:10.1371/journal.pone.0036800.g003
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Axl (lane 2). These results indicated that Tyro3 can be crosss-
phosphorylated by Axl since the kdTyro3 lacks kinase activity. We
then tested whether Tyro3 and Axl co-precipitated as an
indication that the two receptors closely interact.
When Tyro3 immunoprecipitates were blotted with anti-Tyro3
(Fig. 5D lanes 1) monomeric forms of the approximately 125–
120 kDa doublet characteristic of Tyro3 were detected. When the
Tyro3immunoprecipitateswereblottedagainstAxl,wealsodetected
monomericAxl(Fig.5Dlane3).WhenAxlimmunoprecipitateswere
blotted against Axl we detected bands corresponding to monomeric
Axlasexpected(Fig.5Dlane4).WhentheseAxlimmunoprecipitates
were blotted against Tyro3 we also were able to detect it as
demostratedbytnhepresenceofitssignaturedoublet(Fig.5Dlane2).
GiventhattheantibodiesusedagainstTyro3andAxlarespecificfor
eachofthereceptors(seeFig.1)theseexperimentssuggestthatTyro3
and Axl closelyinteract.
Discussion
In this study we explored the mitogenic properties of the
receptor Tyro3 and its interactions with the related receptor Axl.
We also investigated the potential signaling mechanisms mediating
the mitogenic response and determined that the co-expression of
Figure 4. Tyro3 increases Gas6-induced Axl phosphorylation. Rat2 (Rat lanes 1–3) and Rat2/T3V5 cells (Rat/T3, lanes 4–6) were treated
with 0, 50, 350 ng/ml Gas6 for 20 min. Detergent cell lysates were prepared and normalized for protein concentration. The samples were divided in
two for Tyro3 (panel A) and Axl (panel B) immunoprecipitations (IP). This was followed by SDS-PAGE using 8% gels followed and Western blot
analysis. The membranes were probed with anti-phosphotyrosine (a-pTyr) antibodies (PY20 and P99 mixture 1:3,500) (top, panels A and B). The
membranes were stripped and reprobed with a-Tyro3 serum 5424 (1:3,500) (A, bottom panel) or affinity purified rabbit a-Axl (1:3,500) (B, bottom
panel). These blots are representative of 4 experiments. To determine whether Tyro3 expression affects Axl levels in Rat2 cells (panel C), detergent
cell extracts were prepared from Rat2 cells (lane 1), and independently derived stably transfected Rat2/T3V5 cell lines (clone (cl) 25, lane 2; clone
11, lane 3; clone 30, lane 4). SDS-PAGE using 4–20% gels followed by Western blot analysis was performed on these extracts. The membranes
were cut at the level of the 66 kDa marker and the top portion was probed with rabbit a-Tyro3 (5424 serum 1:3,500) or rabbit a-Axl (1:3,500). The
bottom portion of the membranes were blotted with a-GAPDH (1:500). These blots are representative of 5 experiments. To determine if the levels of
Axl phosphorylation depended on the levels of Tyro3 expressed (panel D) Rat2 cells (lanes 1 and 2) and Rat2/T3V5 cell lines cl25 (lanes 3 and 4)
and cl30 (lanes 5 and 6) were activated with media only (0) or 350 ng/ml of Gas6 for 10 min. Detergent cell lysates were prepared and normalized
for protein concentration. The samples were divided in two for Tyro3 and Axl immunoprecipitations (IP). SDS-PAGE using 8% gels followed by
Western blot analysis was performed. The membranes were probed with anti-phosphotyrosine (a-pTyr) antibodies (PY20 and P99 mixture 1:3,500)
(top and third panels). An aliquot of the remaining Axl IPs were reloaded and probed with affinity purified rabbit a-Axl (1:3,500) (second panel
from the top). The membrane corresponding to Tyro3 IP’s was stripped and reprobed with a-Tyro3 serum 5424 (1:3,500) (bottom panel). These
blots are representative of 6 experiments.
doi:10.1371/journal.pone.0036800.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36800Tyro3 and Axl influenced the relative activation of the MAPK and
PI(3)K signaling pathways. Upon treatment with Gas6, expression
of Tyro3 induced an increase in Axl phosphorylation and in turn,
Tyro3 was phosphorylated in trans by Axl indicating a functional
interaction between these TAM receptors.
Gas6 can elicit a proliferative response in several cell types
including NIH-3T3 cells, VSMCs, [32,33], cardiac fibroblasts
[34], mesangial cells [35], prostate cells [36] and Schwann cells
[37] with the mitogenic effects ascribed primarily to Axl and Mer.
The precise role of each of the TAMs has been difficult to assess as
in most cases the presence and activation state of each of the 3
receptors was not evaluated. In human Schwann cells that express
both Axl and Tyro3, Gas6 induced robust cell proliferation and
activation of ERK1/2. Axl may have mitogenic potential in its
own right, since mesangial cells that express Axl but not Tyro3
show a proliferative response to Gas6 in a STAT3 phosphoryla-
tion-dependent manner. The interpretation of this result is
complicated by the potential presence of eyk/Mer, which can
signal through STAT3 to induce cellular transformation
[35,46,47,48].
In Rat2 cells, the introduction of Tyro3 increased Gas6-
mediated proliferation, which appeared to be partially mediated
by the MAPK pathway and not by the PI(3)K pathway. Tyro3
overexpression caused a significant increase of ERK1/2 phos-
phorylation, which was not observed when Axl was overexpressed.
Tyro3 has been shown to activate MAPK signaling in other
systems including cortical neurons [22] and osteoclasts [49].
Figure 5. Axl cross-phosphorylates Tyro3 and both receptors co-immunoprecipitate. Wild-type and kinase dead forms of Tyro3 were
tested for their ability to auto-phosphorylate (panel A) and phosphorylate Axl (panel B). Rat2 cells were transiently transfected kinase dead
(kd)Tyro3 (kdT3, lane 2) or with wild-type (wt) Tyro3 (wtT3, lane 3). The cells were activated with 350 ng/ml of Gas6 for 20 min. After protein
normalization the extracts were divided in two, for Tyro3 immunoprecipitation (IP) (panel A) and for Axl IP (panel B). After SDS-PAGE using 8% gels
and Western blotting, the membranes were probed with anti-phosphotyrosine (a-pTyr) antibodies (PY20 and P99 mixture 1:3,500) (top, panels A
and B). The membranes were stripped and reblotted with a-Tyro3 serum 5424 (1:3,500, a-Tyro3) (panel A bottom) or re-probed with a-Axl
(1:3,500) (panel B bottom). These blots (panels A and B) are representative of 4 experiments. To determine if Axl can induce Tyro3
phosphorylation (panel C) Rat2 cells were transiently transfected with vectors encoding lacz (lane 1), kdTyro3 (kdT3, lane 2), wtTyro3 (wtT3,
lane 3) or doubly transfected with lacz/Axl (lane 4), kdTyro3/Axl (kdT3/Axl, lane 5) and wtTyro3/Axl (wtT3/Axl, lane 6).The cells were activated
with 350 ng/ml of Gas6 for 20 min. After protein normalization the extracts were divided in two, for Tyro3 immunoprecipitation (IP) (top and center
panels) and for Axl IP (bottom panel). After SDS-PAGE in 8% gels and transfer, the membranes were probed with anti-phosphotyrosine (a-pTyr)
(PY20 and P99 mixture 1:3,500) antibodies (top panel), and rabbit a-Axl (bottom panel). The membrane probed with a-pTyr (Tyro3 IPs) was re-
probed with a-Tyro3 (center panel). These blots are representative of 5 experiments. To determine whether Tyro3 and Axl co-immunoprecipitate,
(panel D) Rat2/T3V5 cells were activated with 350 ng/ml Gas6 for 10 min. Detergent extracts were normalized and divided in two, for Tyro3
immunoprecipitation (IP) using a-FN2 Tyro3 antibodies (IP Tyro3, lanes 1 and 3) and for Axl IP using mouse monocolonal a-Axl antibodies (IP Axl,
lanes 2 and 4). The samples were separated by SDS-PAGE using 6% gels and blotted with a-Tyro3 serum 5424 (1:3,500) (lanes 1 and 2) or rabbit a-
Axl antibodies (1:3,500) (lanes 3 and 4). These blots are representative of 4 experiments.
doi:10.1371/journal.pone.0036800.g005
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a significant increase in ERK1/2 phosphorylation but instead
led to a robust activation of AKT as has been previously reported
[16,25]. Although Axl has been previously shown to activate
ERK1/2, the TAM receptor composition of those cells was not
defined [31,34].
A recent study in which Axl expression was enhanced over that
of Tyro3 and Mer showed a modest suppression of cell pro-
liferation in prostate carcinoma cell lines and this reduction could
in turn be blocked by ERK1/2 inhibitors [50] a finding that
differed from an earlier study [36]. Recently, Tyro3 was detected
in a cell line [20] previously used to demonstrate that Axl could
induce both ERK1/2 and PI(3)K activation [51], underscoring the
need to evaluate the specific complement of TAMs expressed.
Consistent with our observations, others studies have failed to
observe ERK1/2 activation and mitogenesis in response to Axl
activation [52].
The inability of PI(3)K inhibitors to block proliferation
suggested that this signaling pathway did not play a significant
role in the Gas6-mediated proliferation in the Rat2/T3V5 cell
line. The introduction of Tyro3 into the Axl-only expressing cell
line reduced the baseline level of activation of several members of
the PI(3)K signaling pathway despite increases in Axl phosphor-
ylation. Tyro3 and Axl have both been previously shown to
activate the PI(3)K signaling pathway [16,25]. Axl has two
consensus binding sites for p85 [52,53] and one of these can bind
both Grb2 and p85 in intact cells [54]. Tyro3 also has a consensus
p85 binding site [29] and has been shown to activate AKT
[22,23], mTOR and p70S6 kinase in cortical neurons [22]. What
are the mechanisms that could account for a decrease in PI(3)K
signaling upon Tyro3 expression? One possibility is that receptor
cross-phosphorylation results in a pattern of tyrosine phosphory-
lation that is unique to the presence of the Axl/Tyro3 receptor
pair leading to a decrease in the association of p85 with one or
more of its binding sites in Tyro3 or Axl. Unique phosphorylation
patterns have been documented for RPTK heterodimers including
members of the PDGF family [55]. Alternatively, the Tyro3/Axl
pairing could result in the association or activation of a molecule
that antagonizes the function of PI(3)K. In this context it is of
interest to note that Axl can bind the phosphatase C1-TEN, [56]
that antagonizes PI(3)K signaling [57].
Receptor heterodimerization and functional cooperativity
among the TAMs has been predicted based on functional
comparisons using single and multiple TAM knockout animals
[18,19,20,40,41,42,58]. We tested this hypothesis based on the
observation that transfection of Rat2 cells Tyro3 resulted in
a significant increase in Axl phosphorylation, the extent which
depended upon the amount of Tyro3 present. The increased
Axl phosphorylation occurred in the absence of any changes in
the level of Axl expression. The increase in Axl phosphorylation
required Tyro3 activity as this increase was not detected when
a kinase inactive form of this receptor (kdTyro3) was in-
troduced. This supports the concept that Tyro3 either directly
or indirectly phosphorylates Axl. In a reciprocal experiment, the
overexpression of Axl resulted in the phosphorylation of
kdTyro3 indicating that Axl can directly or indirectly phos-
phorylate Tyro3. These observations are consistent with two
reports showing that TAM receptor phosphorylation appears to
be interdependent. In one study, Gas6 failed to activate Axl in
platelets isolated from tyro3
2/2 mice, showing that Tyro3 was
required for Gas6 induced Axl phosphorylation [42]. A second
study showed that macrophages utilize Mer for phagocytosis of
apoptotic cells, but a second TAM seems to be required for full
activation of Mer since in axl
2/2/tyro3
2/2 animals the
phosphorylation of Mer is significantly reduced when challenged
with apoptotic cells [41].
Our studies suggest that the TAM receptors Axl and Tyro3 are
capable of cross-phosphorylation which may be either a direct or
indirect process. The co-immunoprecipitation findings reveal that
Tyro3 and Axl are closely associated. Co-precipitation of Tyro3
and Axl has also been observed in the GnRH cell line NLT [20]. It
remains to be determined if this association is the result of direct
heterodimerization between Tyro3 and Axl as has been observed
for several RPTK families including the ErbB [59], PDGF [45],
and VEGFR [60] families.
These results suggest that changes in the expression levels of
TAM receptors, such as those observed during development or
malignant transformation, have significant implications for cell
function. It will be important to determine if the changes in Tyro3
and Axl phosphorylation occur as the result of receptor
heterodimerization which is often acompanied by changes in
ligand binding preferences and receptor affinities that can
influence the signaling properties of a cell. The demonstration
that Tyro3 and Axl can cross-talk sheds new light onto the
mechanisms underlying in vivo observations obtained using TAM
knockout animals suggesting functional interaction among mem-
bers of this receptor family [18,41,42]. Our studies underscore the
need to identify the TAM receptor repertoire when characterizing
the signaling properties underlying functional changes mediated
by TAM ligands.
Materials and Methods
Ethics Statement
All procedures involving animal derived tissue samples and the
production of anti-sera adhered to the guidelines established and
approved by the NIH Guide for the Care and Use of Laboratory
Animals and the Animal Care and Use Protocol #08-078
approved by the Indiana University Institutional Animal Care
and Use Committee.
Antibodies and Reagents
Recombinant human (h)Gas6 and hAxl-FCs was provided by
Amgen Inc. (Thousand Oaks, CA). Antibodies were obtained
from: anti-Axl (AF154) and anti-Mer (AF591) from R&D Systems
(Minneapolis MN), anti-Mer antibody (MKT-101AP) from
FabGennix International Inc, (Frisco, TX); anti-phospho (p)
ERK1/2 (9101), anti-pp70S6kinase (9205), anti-p70S6kinase
(9202), anti-pAKT (9271), anti-AKT (9272), anti-mTOR (2972),
and anti-pmTOR (2971) from Cell Signaling Technology
(Danvers, MA); anti-MAPK (anti-ERK1/2 M-5670), from Sig-
ma-Aldrich (St Louis, MO) anti-phospho-tyrosine (ptyr) PY99 (sc-
7020) and PY20 (sc-508) from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-glyceraldehydephosphodehydrogenase (GAPDH)
(CA92590) from Chemicon (Temecula, CA); horse-radish perox-
idase (HRP) conjugated goat anti-rabbit IgG and goat anti-mouse
IgG from Thermo Scientific Inc, Pierce, (Rockford IL). Polyclonal
rabbit antibodies recognizing the second fibronectin type III
repeat of Tyro3, anti-FN2, were affinity purified in house from
serum 2782 as previously described [43]. Polyclonal rabbit anti-
hAxl was prepared in house as described below.
Full-length murine pCMVSport6.1-Axl cDNA was purchased
from Open Biosystems (Thermo Scientific) (clone # 6313662).
Generation and Purification of Axl Antibodies
Axl antisera were raised in rabbits (Myrtle’s Rabbitry
Thompson’s Station, TN) by using hAxl-Fc receptor bodies [9]
(AMGEN). The immunization regime was previously described in
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NIH Guide for the Care and Use of Laboratory Animals and
a protocol approved by the Indiana University Institutional
Animal Care and Use Committee. Anti-Axl antibodies were
affinity-purified by sequentially passing the anti-Axl serum through
an IgG -Sepharose 4B column (Amersham Biosciences) for
removal of anti-Fc antibodies, followed by incubation of the
eluate with hAxl-Fc Sepharose-4B beads. The purified antibodies
were characterized as previously described for the Tyro3
antibodies [43] and their selectivity for Axl shown in Fig. 1A in
the Results section.
Tyro3 and Axl cDNA Constructs
A full-length V5-tagged Tyro3 construct was generated by
cloning an EcoRI/XhoI fragment from clone 18A [27] into
pCDNA3.1/V5-HisA vector (Invitrogen, Carlsbad, CA). A
segment between the BstEII site and the Tyro3 stop codon was
amplified by PCR using primers designed to clone it in frame to
the XbaI site in the vector upstream of the V5 epitope tag. The
‘‘kinase dead’’ (kd)Tyro3 construct was generated using the
method described by Nelson et al 1989 [61]. Two point mutations
were introduced, the first changing lysine 535 to methionine
(K535M) (A to T at bp1838) and the second introducing an
EcoRV site (C to T at bp 1855) (accession # X78103). The NotI/
BstEII fragment in wild-type Tyro3 was replaced by the one
containing the K-M mutation and the EcoRV site.
Cell Culture and Gas6 Activation
The Rat2 untransfected cells (ATCC, Manassas, VA) were used
to generate the Rat2/T3V5 cells lines as described under ‘‘Cell
Transfection’’. The cells were grown in DMEM, 2 mM L-
glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml)
(all from Invitrogen) and 10% fetal calf serum (FCS) (Omega
Scientific, Tarzana, CA). For Gas6 activation experiments the cells
were serum starved in 0.5% FCS for 48 hrs and replaced with 0%
DMEM for 4 hrs before stimulation. For activation, Gas6 was
added (0, 50 or 350 ng/ml) for 10–20 min at 37uC. When the
activation was performed in the presence of the inhibitors
wortmannin (1.5 mM), LY294002 (5.5 mM) (both from Sigma-
Aldrich), or U0126, (1.0 mM and 10 mM) (Cell Signaling
Technologies) they were added 45 min prior to addition of
Gas6. Dimethylsufoxide (DMSO) (Sigma Aldrich) was used as
vehicle only control. After activation, cell harvesting and lysis were
carried out as previously described [22].
Immunoprecipitation and Western Blotting
For Tyro3, Axl and Mer immunoprecipitation (IPs) from cell
and tissue extracts, lysates containing equal amounts of protein
were incubated overnight at 4uC with primary antibodies. We
used 0.8 mg/ml of affinity-purified anti-FN2 Tyro3 antibody [43],
2.5 mg/ml of anti-Axl # AF154, or 2.5 mg/ml of anti-Mer
#AF591 antibody. For IPs using mouse monoclonal anti-Axl and
anti-Mer antibodies we used 30 ml of a 1:1 Protein G bead/lysis
buffer slurry or for rabbit anti-Tyro3 antibodies 30 ml of a 1:1
Protein A bead/lysis buffer slurry (GE Healthcare). Immunopre-
cipitation and Western blotting was performed using 8% or 4–
20% Tris-glycine gels (Invitrogen) as previously described [22].
The antibodies used for the Western blot analyses were: rabbit
anti-Tyro3 serum #5424 (1:3,500 dilution) [27], rabbit anti-Axl
affinity purified (1:3,500 dilution), rabbit anti-Mer MKT-101AP
(1:2,000 dilution), a 1:1 mixture of anti-pTyr PY99 and PY20
(1:3,500 dilution), anti-ERK1/2 (MAPK) (1:5,000), anti-pERK1/
2, pAKT, AKT, pp70S6kinase, p70S6kinase, pmTOR, mTOR
antibodies were all used at (1:1,000 dilution), and anti-GAPDH
(1:3,500 dilution). Due to variability in the efficiency of stripping
the phosphor-specific antibodies from the blots shown in Fig. 3A
and B the samples were reloaded and blotted with antibodies
recognizing all forms of the proteins in separate gels with the
appropriate controls to ensure equal loading, these data are shown
in Fig. 3C and D.
Deglycosylation
Rat2/T3V5 cell and brain detergent extracts lacking SDS,
corresponding to 10 mg of protein were treated overnight at 37uC
with 500 units of N-glycosidase F (PNGase F) using the PNGase F
kit from New England Biolabs (NEB, Beverly, MA) according to
the manufacturer’s instructions. The reaction was stopped by the
addition of Laemmli sample buffer, denatured for 3 min at 98uC,
and analyzed by SDS-PAGE as described in ‘‘Immunoprecip-
itation and Western Blotting’’.
Cell Proliferation Assay
Rat2 cells and Rat/T3V5 cells (25,000 cells/well) were seeded
in 24 well plates for 24 hrs. The media was changed to 0.5%
serum containing 0–500 ng/ml of Gas6. Pharmacological inhibi-
tors were added 45 min prior to Gas6 addition when used. They
included the PI(3)K inhibitors wortmannin (1.5 mM) and
LY294002 (5.5 mM) the MEK inhibitor U0126, (5.0 mM) and
DMSO as control. For the time-course experiments the cells were
incubated in Gas6 for 0, 24, 48, and 72 hrs with 250 ng/ml of
Gas6. For pathway-inhibitor experiments the incubation period
was 72 hrs with 250 ng/ml of Gas6.
Changes in proliferation were determined using the WST-8, (2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt) (Dojindo, Gaithersburg, MD)
reagent as described by the manufacturers. The optical density of
a total of 4 wells per condition was averaged in each experiment,
and the results of three independent experiments were averaged
using the 2-sample t-test.
Cell Transfection
Rat2 cells were plated in 6 well plates at a density of 0.4610
6
cells/well and were transfected with pcDNA3.1/Tyro3V5-HisA
vector (Invitrogen) encoding full-length mouse Tyro3, or
pCDNA3.1/laczV5-HisA using Lipofectamine Plus following
manufacturer instructions (Invitrogen). Neomycin resistant clones
were selected with 600 mg/ml G418 (Omega Scientific) and tested
for Tyro3 expression as previously described [43]. Our efforts to
perform signaling and proliferation experiments in Rat2 cell lines
overexpressing Axl after selection of permanently transfected cells
were not feasible. Despite considerable effort, we were unable to
obtain lines that expressed Axl at levels over those observed in
untransfected cells. We tested 3 different Axl constructs, utilized
multiple transfection protocols and selected and screened over 200
antibiotic resistant lines.
For transient transfection experiments with 2 plasmids, Rat2
cells were plated in 6 well plates at a density of 0.4610
6 cells/well
and transfected as described above with 2 mg of wtTyro3/V5,
kdTyro3/V5 or lacZ/V5 or by combining these vectors with 4 mg
of Axl cDNA. The cells were grown for 24 hrs before changing the
media overnight to 0.5% serum, and again to no serum 4 hours
before the activation experiments were performed.
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